Abstract
Biliverdin reductase-A is a pleiotropic enzyme involved not only in the reduction of biliverdin-IX-alpha into bilirubin-IX-alpha, but also in the regulation of glucose metabolism and cell growth secondary to its serine/threonine/tyrosine kinase activity. Together with heme oxygenase, whose metabolic role is to degrade heme into biliverdin-IX-alpha, it forms a powerful system involved in the cell stress response during neurodegenerative disorders. In this paper, an up-regulation of the biliverdin reductase-A protein levels was found in the hippocampus of the subjects with Alzheimer disease and arguably its earliest form, mild cognitive impairment. Moreover a significant reduction in the phosphorylation of serine, threonine and tyrosine residues of biliverdin reductase-A was found, and this was paralleled by a marked reduction in its reductase activity. Interestingly, the levels of both total and phosphorylated biliverdin reductase-A were unchanged as well as its enzymatic activity in the cerebella. These results demonstrated a dichotomy between biliverdin reductase-A protein levels and activity in the hippocampus of subjects affected by Alzheimer disease and mild cognitive impairment, and this effect likely is attributable to a reduction in the phosphorylation of serine, threonine and tyrosine residues of biliverdin reductase-A. Consequently, not just the increased levels of biliverdin reductase-A, but also its changed activity and phosphorylation state, should be taken into account when considering potential biomarkers for Alzheimer disease and mild cognitive impairment.
Original language | English |
---|---|
Pages (from-to) | 480-487 |
Number of pages | 8 |
Journal | Biochimica et Biophysica Acta - Molecular Basis of Disease |
Volume | 1812 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2011 |
Bibliographical note
Funding Information:This work was supported in part by a NIH grant to D.A.B. [ AG-05119 ]. E.B. is a Ph.D. student of the Catholic University of the Sacred Heart in Rome and is recipient of fellowships from the Society for Free Radical Biology and Medicine and the Italian Society of Pharmacology . F.D.D. was supported by a fellowship from Istituto Pasteur-Fondazione Cenci Bolognetti . We are grateful to the Neuropathology Cores of the University of Kentucky Alzheimer's Disease Clinical Center for providing well-characterized specimens for this research. The authors state that they have no conflict of interests associated with this study.
Funding
This work was supported in part by a NIH grant to D.A.B. [ AG-05119 ]. E.B. is a Ph.D. student of the Catholic University of the Sacred Heart in Rome and is recipient of fellowships from the Society for Free Radical Biology and Medicine and the Italian Society of Pharmacology . F.D.D. was supported by a fellowship from Istituto Pasteur-Fondazione Cenci Bolognetti . We are grateful to the Neuropathology Cores of the University of Kentucky Alzheimer's Disease Clinical Center for providing well-characterized specimens for this research. The authors state that they have no conflict of interests associated with this study.
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | |
National Institute on Aging | P01AG005119 |
Istituto Pasteur-Fondazione Cenci Bolognetti |
Keywords
- Alzheimer disease
- Biliverdin reductase
- Cerebellum
- Hippocampus
- Mild cognitive impairment
- Oxidative stress
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology